Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DALY 2-EU trial of MB-CART2019.1 versus standard of care in relapsed/refractory diffuse large B-cell lymphoma
2023-506270-13-00Phase 2Authorised
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Jul 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 16
01
Overview
Phase 2, randomised, open-label trial of zamtocabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Miltenyi Biomedicine GmbH. Primary endpoints: Event-free survival and Best objective response rate. Planned start Jul 2021; status: authorised.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2023-506270-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506270-13-00.